Biogen and Japan’s Eisai said on Friday the U.S. Food and Drug Administration has accepted their marketing application for experimental Alzheimer’s disease treatment aducanumab.
Source: Business - cnbc.com
Biogen and Japan’s Eisai said on Friday the U.S. Food and Drug Administration has accepted their marketing application for experimental Alzheimer’s disease treatment aducanumab.
Source: Business - cnbc.com